Botulinum Toxin A for Chronic Migraines: Clinical Effectiveness
**Authors:** Wendy Pejic, Lorna Adcock


**Acknowledgments:**

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Research Questions

1. What is the clinical effectiveness of botulinum toxin A for patients with chronic migraines?

2. What is the clinical effectiveness of botulinum toxin A plus opioid derivatives for patients with chronic migraines?

Key Findings

Two systematic reviews, six randomized controlled trials, and two non-randomized studies were identified regarding the clinical effectiveness of botulinum toxin A for patients with chronic migraines.

Methods

A limited literature search was conducted on key resources including Ovid Medline, Ovid Embase, PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases and a focused Internet search. No methodological filters were applied to limit retrieval by publication type. The search was limited to English language documents published between January 1, 2013 and December 12, 2017. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

<table>
<thead>
<tr>
<th>Population</th>
<th>Patients with chronic migraines</th>
</tr>
</thead>
</table>
| Interventions | Q1: Botulinum toxin A:  
  - OnabotulinumtoxinA (Botox);  
  - IncobotulinumtoxinA (Xeomin);  
  - AbobotulinumtoxinA (Dysport Therapeutic)  
Q2: Botulinum toxin A + an opioid derivative (e.g., codeine) |
| Comparators |  
  - Pharmacotherapy interventions, including:  
    - Tricyclic antidepressants  
    - Beta blockers  
    - Anticonvulsants  
    - Calcium channel blockers  
    - Serotonin-norepinephrine reuptake inhibitors  
  - Non-pharmacological interventions, including:  
    - Behavioural therapies  
    - Physical therapy  
    - Lifestyle modifications  
    - Natural products  
  - Placebo |
| Outcomes | Q1: Clinical effectiveness (benefit/harm), reduction in headache/migraine episodes, safety |
Q2: Opioid usage outcomes (e.g., number of patients who cease opioid usage, reduction in opioid usage), clinical effectiveness (benefit/harm), safety

| Study Designs | Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies |

**Results**

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials and non-randomized studies.

Two systematic reviews, six randomized controlled trials, and two non-randomized studies were identified regarding the clinical effectiveness of botulinum toxin A for patients with chronic migraines. No relevant health technology assessments or meta-analyses were identified.

Additional references of potential interest are provided in the appendix.

**Overall Summary of Findings**

Two systematic reviews (SRs),\(^1\)\(^-\)\(^2\) six randomized controlled trials,\(^3\)\(^-\)\(^8\) and two non-randomized studies\(^9\)\(^-\)\(^10\) were identified regarding the clinical effectiveness of botulinum toxin A (BTX-A) for patients with chronic migraines (CM). Detailed study characteristics are provided in Table 2.

Conclusions from most of the identified studies\(^2\)\(^-\)\(^5\),\(^6\)\(^-\)\(^9\),\(^10\) (and pooled analyses of the PREEMPT trial\(^3\)\(^-\)\(^7\)) indicated that BTX-A provided some relief for patients with CM; however, it was observed to be associated with increased risks of adverse events and withdrawals due to adverse events in one SR.\(^2\) Conversely, the authors of the other identified SR that met the inclusion criteria concluded that there was uncertainty associated with whether BTX-A reduced the frequency of headache days and acute headache pain medication or was associated with any impact on functioning when compared to placebo.\(^1\)

**Table 2: Description of the Included Studies and Their Conclusions**

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Study Characteristics</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
<th>Conclusions</th>
</tr>
</thead>
</table>
| Kim et al.,\(^1\) 2014 | • Comparing BTX injection to PL (saline) in patients with CM  
  • 6 publications describing 3 PL-controlled RCTs included  
  • N=1444 | • BTX-A | • Placebo (saline injections) | • Frequency of headache days  
  • Reduction in acute headache pain medication  
  • Impact on functioning | • Uncertain whether BTX reduces frequency of headache days, acute headache pain medication, or has any impact on functioning when compared to saline  
  • BTX may result in little/no difference in headache hours |

**Systematic Reviews**
Table 2: Description of the Included Studies and Their Conclusions

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Study Characteristics</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
<th>Conclusions</th>
</tr>
</thead>
</table>
| Shamliyan et al, 2013 | • Assessing comparative effectiveness and safety for community-dwelling adults with CM or episodic migraines<sup>a</sup>  
• 245 publications of RCTs and 76 NRS included  
• BTX formulations examined in N=4,237 (20 RCTs) | • BTX formulations | • Inactive controls (PL)  
• Non-pharmacologic interventions  
• Other drugs | • Prevention of CM or episodic migraines<sup>a</sup> | • BoNTA more effective at reducing month CM attacks (≥50%) compared with PL (low strength evidence from 3 RCTs, n=459)  
• BoNTA produced inconsistent improvements in QoL  
• Per 1000 treated adults:  
  o 170 (95% CI 82 – 258) would experience ≥50% reduction in migraine frequency  
  o 155 (95% CI 90 to 220) would experience adverse effects  
  o 26 (95% CI 10-43) would WDAE  
• No differences in CM prevention were identified when comparing BoNTA with topiramate and divalproex |  |

**Randomized Controlled Trials**

| Matharu et al. 2017<sup>3</sup> | • Determine whether BoNTA has impact on headache-day severity in non-responding patients with CM  
• Pooled analysis of data from PREEMPT  
• 24-week, 2-treatment cycle, | • BoNTA | • PL | • Reduction in number of severe headache days  
• Average daily headache severity | • Patients with CM deemed non-responders (based on analysis of headache frequency alone) appear to achieve clinical meaningful relief from headache intensity upon receiving BoNTA when compared to PL after 24 weeks  
• Between group differences were |
## Table 2: Description of the Included Studies and Their Conclusions

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Study Characteristics</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipton et al., 2016&lt;sup&gt;4&lt;/sup&gt;</td>
<td>parallel, DB PL-controlled trial followed by 32-week, 3-treatment cycle OL phase</td>
<td>BoNTA (DB phase)</td>
<td>PL (DB phase)</td>
<td>HRQoL endpoints (over 56 weeks); including HIT-1 and MSQ</td>
<td>Benefits of BoNTA on HRQoL versus baseline were evident through the OL phase</td>
</tr>
<tr>
<td></td>
<td>Patients with CM from PREEMPT</td>
<td>O/O (OL phase; n=607)</td>
<td>P/O (OL phase; n=629)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N=1,236</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>DB RCT phase (24 weeks) followed by 36 week OL phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shehata et al., 2016&lt;sup&gt;5&lt;/sup&gt;</td>
<td>Pilot RCT comparing rTMS vs BTX-A</td>
<td>BTX-A (n=15)</td>
<td>rTMS (n=14)</td>
<td></td>
<td>Reduction of all outcomes measures observed in both treatment groups</td>
</tr>
<tr>
<td></td>
<td>N=29</td>
<td></td>
<td></td>
<td></td>
<td>The reductions in all outcome measures were more sustained in the BTX-A group</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Both therapies were well tolerated</td>
</tr>
<tr>
<td>Hou et al, 2015&lt;sup&gt;5&lt;/sup&gt;</td>
<td>Compared the fixed (muscle) – site and acupoint-site injections with BoNTA and PL</td>
<td>BoNTA (2.5 U each site, 25 U per subject) injection at fixed-sites (n = 41); including occipitofrontalis, corrugator supercilii, temporalis and trapezius</td>
<td>PL (n=19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patients had either CM or episodic migraines&lt;sup&gt;5&lt;/sup&gt;</td>
<td>BoNTA acupoint-sites (n = 42); including Yintang (EX-HN3), Taiyang (EX-HN5), Baihui (GV20), Shuagiu (GB8), Fengchi</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Efficacy of fixed-versus acupoint injection at reducing frequency, intensity, and duration</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acupoint injections of BoNTA appear to show more efficacy than fixed-site injections</td>
</tr>
</tbody>
</table>
### Table 2: Description of the Included Studies and Their Conclusions

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Study Characteristics</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silberstein et al., 2015&lt;sup&gt;7&lt;/sup&gt;</td>
<td>• To assess whether treatment non-responders (from cycle 1) will respond in cycle 2 and whether treatment non-responders (from cycles 1 and 2) will respond in cycle 3 • Used pooled data from the PREEMPT trial</td>
<td>(GB20) and Tianzhu (BL10).</td>
<td>• BoNTA (n=688)</td>
<td>• PL</td>
<td>• Non-responders response to subsequent cycles of treatment with BoNTA • Cumulative hours of headache and HRQoL outcomes</td>
</tr>
<tr>
<td>Aurora, et al., 2014&lt;sup&gt;8&lt;/sup&gt;</td>
<td>• Patients with CM were part of the PREEMPT trial • This is a secondary assessment of patients receiving 5 treatment cycles • N=1,005</td>
<td>BoNTA (O/O; n=513)</td>
<td>PL (n=492:2 cycles of PL and 3 cycles of BoNTA [P/O])</td>
<td>Multiple headache symptom measures</td>
<td>This subgroup analysis demonstrated improvements in O/O with the multiple headache outcomes compared to the P/O group • These results suggest that better outcomes were achieved in those patients on BoNTA earlier (with outcomes assessed at 56 weeks)</td>
</tr>
<tr>
<td>Dodick et al., 2015&lt;sup&gt;9&lt;/sup&gt;</td>
<td>• Assessed results from the PREEMPT trial and a topiramate trial • Patients with CM</td>
<td>BoNTA</td>
<td>Topiramate</td>
<td>Headache prophylaxis in CM (frequency headache days and migraine days) • Responder rates, HRQoL, safety, tolerability, and discontinuation</td>
<td>Statistically significant and clinically relevant treatment benefits were evident from the clinical data for both BoNTA and topiramate • The results support the use of both agents for meaningful headache prophylaxis in CM</td>
</tr>
<tr>
<td>Diener et al., 2014&lt;sup&gt;10&lt;/sup&gt;</td>
<td>• Pooled analysis from 4 DB PL-</td>
<td>BoNTA</td>
<td>PL</td>
<td>Safety and tolerability</td>
<td>Multiple treatments with BoNTA doses of 75-260 U</td>
</tr>
</tbody>
</table>
Table 2: Description of the Included Studies and Their Conclusions

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Study Characteristics</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>controlled RCTs (two phase II and two phase III)</td>
<td>N=2,436 (n=1,997 received ≥ 1 dose of BoNTA)</td>
<td>administered every 12 weeks were tolerated well in patients with CM</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AE – adverse event; BTX = botulinum toxin; BTX-A = botulinum toxin A; BoNTA = Onabotulinumtoxin A; CI = confidence interval; CM = chronic migraine; DB = double blind; HDI = Henry Ford Hospital Headache Disability Inventory; HIT-1 = Headache Impact Test; HRQoL = health-related quality of life; MSQ = Migraine-Specific Quality of Life Questionnaire; NRS = non-randomized studies; OL = open label; PL = P/O = placebo/BoNTA; PL = placebo/BoNTA; PREEMPT = Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy; QoL = quality of life; RCT = randomized controlled trial; tMS = repetitive transcranial magnetic stimulation; WDAE = withdraw due to adverse events.

a Information regarding episodic migraines is not provided; only for CM.

References Summarized

Health Technology Assessments

No literature identified.

Systematic Reviews and Meta-analyses


Randomized Controlled Trials


Non-Randomized Studies


Appendix — Further Information

Previous CADTH Reports


Randomized Controlled Trials

Currently Recruiting


Alternative Population – Patients with Chronic Migraines and Co-Morbidities


Alternative Intervention – Combined Intervention


Non-Randomized Studies

No Comparator


No Comparator - Patients with Chronic Migraine and Acute Headache Medication Overuse


No Comparator - Refractory/Resistant Migraines


Alternative Outcome


Botulinum Toxin A for Chronic Migraines

14 Aug;36(9):862-74.
PubMed: PM26692400

Alternative Population – Patients with Chronic Migraines and Co-Morbidities

PubMed: PM26753113

Non-Completed Studies

PubMed: PM28879545

Qualitative Studies

PubMed: PM28667550

Case Series Involving Incobotulinumtoxin A

PubMed: PM26166734

Economic Evaluations

PubMed: PM28132276

PubMed: PM25298117


PubMed: PM23647483
